A Phase 1/2 interventional study of Ex Vivo Immunotherapy and Ex vivo immunotherapy in Anemia, Aplastic, sponsored by Shenzhen Zhongxing Yangfan Biotech Co. Ltd.. Status unknown at 1 site in China. Open to participants aged 10 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-11-11.
Sponsored by Shenzhen Zhongxing Yangfan Biotech Co. Ltd. · Phase 1/2, Interventional, and Treatment
Our hypothesis is that ex vivo activated immune cells would produce multiple known and unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell growth and differentiation. Additionally, these cells travel and home to bone marrow as well as spleen and liver involved in hematopoietic activities, where direct cell-cell contact may be beneficial.
Patients will be required to stay in our hospitals to receive the immunotherapy. Allogeneic peripheral blood mononuclear cells from healthy donors and the autologous peripheral mononuclear cells will alternately used for the treatment. Patients are expected to spend at least 6 to 12 months in the hospital and won't be released until they have improved significantly.
1,733 studies on the registry are indexed under Anemia; 246 are open to participants now.
This study's planned enrollment of 100 is close to the median of 94 across 1,291 interventional studies indexed under Anemia.
Browse Anemia studies →This is the only study on the registry with Shenzhen Zhongxing Yangfan Biotech Co. Ltd. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will receive cell-based immunotherapy.
Procedure: Ex Vivo Immunotherapy · Drug: Ex vivo immunotherapy
Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
Also known as: Aplastic Anemia, ex vivo Immunotherapy
i.v. infusions, once a week, at least 6 to 12 months
Also known as: Aplastic Anemia, ex vivo Immunotherapy
Survival
Time frame: 2 years
Hematological Parameters
Time frame: 2 years
Hematopoietic Activities in Bone Marrow
Time frame: 2 years
Quality of Life
Time frame: 2 years
This study is status unknown, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.